2300178-76-9
2300178-76-9
Chemical Structure
Moricizine-d8 Hydrochloride
Synonym(s): EN 313-d8;Ethmozin-d8;Moracizine-d8
- CAS No.: 2300178-76-9
- Formula:C22H18D8ClN3O4S
- Molecular Weight:472.03
IUPAC Name: ethyl (10-(3-(morpholino-d8)propanoyl)-10H-phenothiazin-2-yl)carbamate hydrochloride
InChIKey: GAQAKFHSULJNAK-USILMEKGSA-N
SMILES: [2H]C1([2H])C([2H])([2H])OC([2H])([2H])C([2H])([2H])N1CCC(N2C3=CC(NC(OCC)=O)=CC=C3SC4=CC=CC=C42)=O.Cl
Biological Activity: Moricizine-d8 Hydrochloride (EN 313-d8; Ethmozin-d8; Moracizine-d8) is the deuterated-labeled Moricizine Hydrochloride (HY-B0615A). Moricizine Hydrochloride (EN 313) is an orally active cardiac sodium channel blocker. Moricizine Hydrochloride blocks inactivated sodium channels in a slow dissociation manner, inhibiting late and peak sodium currents, p-CaMKII, atrial enlargement, and cardiac hypertrophy. Moricizine Hydrochloride can be used in research on atrial fibrillation and arrhythmias[1][2][3][4][5][6][7].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Moricizine-d8 Hydrochloride | 99.61% | Moricizine-d8 Hydrochloride (EN 313-d8; Ethmozin-d8; Moracizine-d8) is the deuterated-labeled Moricizine Hydrochloride (HY-B0615A). Moricizine Hydrochloride (EN 313) is an orally active cardiac sodium channel blocker. Moricizine Hydrochloride blocks inactivated sodium channels in a slow dissociation manner, inhibiting late and peak sodium currents, p-CaMKII, atrial enlargement, and cardiac hypertrophy. Moricizine Hydrochloride can be used in research on atrial fibrillation and arrhythmias. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Moricizine Hydrochloride | 98.0% | Moricizine Hydrochloride (EN 313) is an orally active cardiac sodium channel blocker. Moricizine Hydrochloride blocks inactivated sodium channels in a slow dissociation manner, inhibiting late and peak sodium currents, p-CaMKII, atrial enlargement, and cardiac hypertrophy. Moricizine Hydrochloride can be used in research on atrial fibrillation and arrhythmias. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Metopimazine | 99.75% | Metopimazine (EXP999; RP9965) is a phenothiazine, orally available, selective dopamine D2 receptor antagonist that does not penetrate the blood-brain barrier. Metopimazine blocks dopamine D2 receptors in the chemoreceptor trigger zone and the periphery, thereby inhibiting nausea and vomiting. Metopimazine is indicated for chemotherapy-induced nausea and vomiting, and has low central side effects due to its poor brain penetration. The use of metopimazine in acute gastroenteritis may have potential risks. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Chloracyzine | Chloracyzine is an antianginal agent with spasmolytic properties and prevent or relieve spasms of the coronary vessels. Chloracyzine shows a moderate antihistaminic effect. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tiracizine hydrochloride | Tiracizine hydrochloride (AWD-19-166) is a Class I antiarrhythmic drug with activity that reduces myocardial contractile function. Tiracizine hydrochloride was studied in patients with ischemic heart disease, showing its effects on the myocardium. Tiracizine hydrochloride reduces myocardial contractility and may have potential use in the management of heart disease. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ethacizine | Ethacizine is an antiarrhythmic agent and analog of Ethmozine (HY-B0615A). Ethacizine inhibits ventricular premature beats. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ethacizine hydrochloride | 99.25% | Ethacizine hydrochloride (Ethacizin) is an antiarrhythmic agent and analog of Ethmozine (HY-B0615A). Ethacizine hydrochloride inhibits ventricular premature beats. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
LSD1/TLK1-IN-1 | 99.20% | LSD1/TLK1-IN-1 is an orally active LSD1, TLK1, TLK2, TTK inhibitor with an LSD1 IC50 of 0.247 μM. LSD1/TLK1-IN-1 suppresses phosphorylation of Nek1 at T141 and Rad9 at S328, abrogates the TLK1>Nek1>ATR>Chk1 axis, protects H3K4me1/2 from demethylation, and does not affect LSD2, MAO-A, or MAO-B. LSD1/TLK1-IN-1 induces apoptosis, bypasses cell-cycle arrest, suppresses tumor growth, downregulates PD-L1 expression, enhances T-cell killing response, inhibits gastric cancer cell proliferation. LSD1/TLK1-IN-1 can be used for the research of prostate cancer and gastric cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Perphenazine dihydrochloride | Perphenazine dihydrochloride is an orally active dopamine receptor and histamine-1 receptor antagonist, with Ki values of 0.56 nM (D2), 0.43 nM (D3), 6 nM (5-HT2A), respectively. Perphenazine dihydrochloride also binds to Alpha-1A adrenergic receptor. Perphenazine dihydrochloride inhibits cancer cell proliferation, and induces apoptosis. Perphenazine dihydrochloride can be used in the research of mental disease, cancer, inflammation. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Trifluoperazine dihydrochloride | 99.94% | Trifluoperazine dihydrochloride, an antipsychotic agent, acts by blocking central dopamine receptors. Trifluoperazine dihydrochloride is a potent α1-adrenergic receptor antagonist. Trifluoperazine dihydrochloride is a potent NUPR1 inhibitor exerting anticancer activity. Trifluoperazine dihydrochloride is a calmodulin inhibitor, and also inhibits P-glycoprotein. Trifluoperazine dihydrochloride can be used for the research of schizophrenia. Trifluoperazine dihydrochloride acts as a reversible inhibitor of influenza virus morphogenesis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Thiethylperazine (Standard) | ≥98% | Thiethylperazine (Standard) is the analytical standard of Thiethylperazine. This product is intended for research and analytical applications. Thiethylperazine, a phenothiazine derivate, is an orally active and potent dopamine D2-receptor and histamine H1-receptor antagonist. Thiethylperazine is also a selective ABCC1activator that reduces amyloid-β (Aβ) load in mice. Thiethylperazine has anti-emetic, antipsychotic and antimicrobial effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zou T, et al. Moricizine prevents atrial fibrillation by late sodium current inhibition in atrial myocytes. Journal of thoracic disease. 2022 Jun;14(6):2187-2200.
- [2]. Han C, et al. Clock-Modulating Activities of the Anti-Arrhythmic Drug Moricizine. Clocks & sleep. 2021 Jun 22;3(3):351-365.
- [3]. Konishi H, et al. Moricizine, an antiarrhythmic agent, as a potent inhibitor of hepatic microsomal CYP1A. Pharmacology. 2002 Dec;66(4):190-8.
- [4]. Abalakov GA, et al. Moricizine (ethmozine) can break electrical coupling between rat right atrial working cardiomyocytes in vitro. Bulletin of Experimental Biology and Medicine. 2018 Jul;165(3):351-5.
- [5]. Ahmmed GU, et al. Analysis of moricizine block of sodium current in isolated guinea-pig atrial myocytes. Atrioventricular difference of moricizine block. Vascular pharmacology. 2002 Mar;38(3):131-41. [Content Brief]
- [6]. Saeki T, et al. Block of Na+ channel by moricizine hydrochloride in isolated feline ventricular myocytes. European journal of pharmacology. 1994 Aug 22;261(3):249-56.
- [7]. Maruyama K, et al. Electrophysiological effects of Ro 22-9194, a new antiarrhythmic agent, on guinea-pig ventricular cells. British journal of pharmacology. 1995 Jan;114(1):19-26.
